Research programme: pain therapeutics - PhytoPain Pharma

Drug Profile

Research programme: pain therapeutics - PhytoPain Pharma

Alternative Names: PPP-001; PPTGR

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator PhytoPain Pharma
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neuropathic pain

Most Recent Events

  • 01 Feb 2017 Therapeutic Products Directorate, Health Canada, approves IND application for PPTGR in Pain (Chemotherapy-induced neuropathic pain)
  • 30 Jan 2017 PhytoPain plans a phase I trial Healthy volunteers in USA
  • 23 Jan 2017 PhytoPain Pharma enters into an agreement with Sante Cannabis for the development of late phase clinical trial protocols for PPP 001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top